|View printer-friendly version|
Spring Bank Pharmaceuticals Reports First Quarter 2020 Financial and Operational Results
Continues to advance IV SB 11285 clinical trial to additional dosing cohorts
On track to include Roche’s Tecentriq® in IV SB 11285 clinical trial in summer 2020
Advancing efforts to examine RIG-I and
“Despite the negative impact of the COVID-19 pandemic on the conduct of clinical trials throughout our industry, we have been fortunate to find ways to continue to dose patients in our SB 11285 Phase 1a/1b trial through the exceptional efforts of our principal investigator and the
Recent Highlights and Business Developments
2020 First Quarter Financial Results
Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including whether Spring Bank’s product candidates will advance through the clinical trial process on a timely basis, or at all; whether Spring Bank’s cash resources will be sufficient to fund its continuing operations for the periods and/or trials anticipated; whether the results of the company’s trials will warrant submission for approval from the
In addition, the forward-looking statements included in this press release represent Spring Bank’s views as of the date hereof.
Source: Spring Bank Pharmaceuticals, Inc.